Description: NPS Pharmaceuticals, Inc.
NPS Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development of specialty therapeutics for gastrointestinal and endocrine disorders. The company is advancing two late-stage programs to restore or replace biological function, including GATTEX (teduglutide), which is in Phase 3 clinical development for parenteral dependent short bowel syndrome; and NPSP558 (parathyroid hormone 1-84 [rDNA origin] injection) that is in Phase 3 clinical development as a hormone therapy for hypoparathyroidism. It has collaboration and license agreements with Amgen Inc.; AstraZeneca AB; GlaxoSmithKline; Kyowa Kirin; Nycomed; Ortho-McNeil Pharmaceuticals, Inc.; Hoffman-La Roche Inc.; and F. Hoffmann-La Roche Ltd. The company was founded in 1986 and is based in Bedminster, New Jersey.